title: Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia.
abstract: BACKGROUND
  The high use of long-term antiparkinsonian anticholinergic drugs with antipsychotics has been identified as an important issue in the treatment of schizophrenia in Japan. The aim of this study was to evaluate the effects of gradual discontinuation of biperiden, an anticholinergic drug, on cognitive function and quality of life (QOL) in schizophrenia.
  
  
  METHODS
  Thirty-four schizophrenic patients who had received a second-generation antipsychotic (SGA) with concomitant biperiden for at least 3 months were enrolled. Before and 4 weeks after discontinuation of biperiden, the Japanese version of the Brief Assessment of Cognition in Schizophrenia (BACS-J) and the Schizophrenia Quality of Life Scale (SQLS-J) were administered. Clinical evaluation also included the Positive and Negative Syndrome Scale (PANSS). To compare the practice effect on BACS-J, 10 chronic patients with schizophrenia were assessed without tapering biperiden.
  
  
  RESULTS
  Biperiden was discontinued safely in most patients, and no emergent extrapyramidal symptoms were observed. Significant improvements were shown in attention, processing speed, and composite score, as measured by the BACS-J without practice effect. In addition, the psychosocial condition score on the SQLS-J and the general psychopathology score on the PANSS significantly improved after biperiden discontinuation.
  
  
  CONCLUSIONS
  Discontinuation of long-term biperiden use may be warranted in patients with schizophrenia treated with SGAs, as it may improve cognitive function, subjective QOL, and psychiatric symptoms with no significant adverse effects.
authors.affiliation: Department of Neuropsychiatry, St Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. OginoshinNo.1@marianna-u.ac.jp
authors.forename: Shin
authors.initials: S
authors.lastname: Ogino
authors.forename: Seiya
authors.initials: S
authors.lastname: Miyamoto
authors.forename: Tomomi
authors.initials: T
authors.lastname: Tenjin
authors.forename: Rei
authors.initials: R
authors.lastname: Kitajima
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Ojima
authors.forename: Nobumi
authors.initials: N
authors.lastname: Miyake
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Funamoto
authors.forename: Jun
authors.initials: J
authors.lastname: Arai
authors.forename: Sachiko
authors.initials: S
authors.lastname: Tsukahara
authors.forename: Yukie
authors.initials: Y
authors.lastname: Ito
authors.forename: Masanori
authors.initials: M
authors.lastname: Tadokoro
authors.forename: Kiriko
authors.initials: K
authors.lastname: Anai
authors.forename: Shinobu
authors.initials: S
authors.lastname: Tatsunami
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kubota
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kaneda
authors.forename: Noboru
authors.initials: N
authors.lastname: Yamaguchi
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001712:Biperiden / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D018727:Muscarinic Antagonists; D001712:Biperiden